Majority
OPINION OF THE COURT
This consolidated action was commenced on behalf of three children, Ralisha, Mercedes and Larissa, seeking damages for injuries sustained as a result of their ingestion of lead-based paint during their residence in apartments owned or maintained by defendants from 1991 to 1993. Supreme Court granted defendants’ motions for summary judgment dismissing the action solely on the ground that plaintiffs failed to establish a causal connection between the children’s injuries and exposure to lead. Plaintiffs now appeal. Asserting that lead poisoning itself is an actionable injury, plaintiffs argue that Supreme Court improperly dismissed the action because the expert medical affidavits submitted in support of defendants’ motions failed to make a prima facie showing that, as a matter of law, there is no causal connection between the children’s exposure to lead paint and their claimed injuries. We agree.
“[T]he proponent of a summary judgment motion must make a prima facie showing of entitlement to judgment as a matter of law, tendering sufficient evidence to demonstrate the absence
As to claims for a child’s exposure to lead, the Court of Appeals has held that prima facie causation is established by evidence that the child’s residence contained a hazardous level of lead-based paint and that the child was observed ingesting paint fragments, had elevated lead levels,[1] was not out of the parent’s custody for any substantial period of time and did not manifest the pertinent symptoms before moving into the residence (s ee, Juarez v Wavecrest Mgt. Team, 88 NY2d 628 , 648). Here, plaintiffs allege and defendants do not dispute that the children had elevated lead levels in their blood measured by tests administered in 1993 and 1994,[2] that they received medical treatment for those elevated levels, that lead-based paint was present in their residences at the relevant times, that they were observed ingesting particles of such paint, that they resided continuously at those residences and that they became ill while living in those residences. Thus, the threshold issue on this appeal is whether the proof in support of defendants’ motions was sufficient to shift the burden to plaintiffs to present more than this prima facie evidence of causation.
Defendants supported their motions with the affidavits of Phillip Riback, a physician specializing in pediatric neurology, and Robert McCaffrey, a neuropsychologist. Basing their opinions upon, inter alia, their examinations of each infant in 1999, a review of the depositions, and detailed histories from the custodians and biological mother, these experts opined that the children’s existing conditions were primarily related to factors other than their exposure to lead.
However, after review of these opinions in the light most favorable to plaintiffs, we conclude that defendants did not
1 “Elevated lead levels” is defined in Public Health Law § 1370 (6) as “a blood lead level greater than or equal to ten micrograms of lead per deciliter [mg/dl] of whole blood or such blood lead level as may be established by the department pursuant to rule or regulation” (see, 10 NYCRR 67-1.1 [d]).
2 Blood test results indicated that at various times in 1993, Ralisha had levels of 35 mg/dl, Larissa had levels of 32 mg/dl and Mercedes had levels of 63 mg/dl.
As there is no dispute that the levels of lead measured in the children’s blood in 1993 and 1994 are recognized as elevated, unhealthy and requiring remedial medical treatment,[3] such as the chelation and provocation inpatient therapies undergone
3 The Centers for Disease Control and Prevention have stated that “[b]lood lead levels (BLLs) as low as 10 mg/dl are associated with harmful effects on children’s ability to learn” (Centers for Disease Control and Prevention, Screening Young Children for Lead Poisoning: Guidance for State and Local Public Health Officials, at 13, Nov. 1997, published on the Internet at <http://www.courts.state.ny.us/reporter/webdocs/leadguide97.pdf>). The Department of Health has recognized that such levels are of concern by mandating the reporting of all blood-lead tests at or above 10 mg/dl (see, 10 NYCRR 67-3.3; see also, statement of legislative findings and purposes, L 1970, ch 338, § 1 [Public Health Law § 1370 et seq.]).
Crew III, J. P., Spain, Mugglin and Lahtinen, JJ., concur.
Ordered that the order entered January 13, 2000 is reversed, on the law, with costs, and matter remitted to the Supreme Court for further proceedings not inconsistent with this Court’s decision.
Ordered that the appeal from the order entered February 28, 2000 is dismissed, as academic.
Cases cited
- Alvarez v. Prospect Hospital 68 NY2d 320 at 324 p. 95
- Horth v. Mansur 243 AD2d 1041 at 1042 p. 95
- Juarez v. Wavecrest Management Team Ltd. 88 NY2d 628 at 648 p. 95
- Stewart v. New York City Health & Hospitals Corp. 207 AD2d 703 at 704 p. 97